Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double‐blind Phase Ib study

The immunoregulator spleen tyrosine kinase (SYK) is upregulated in cutaneous lupus erythematosus (CLE). This double‐blind, multicentre, Phase Ib study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of the selective SYK inhibitor GSK2646264 in active CLE...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Alex, Erwig, Lars, Foster, Katie, Nevin, Katherine, Wenzel, Joerg, Worm, Margitta, Williams, Nicola, Ratia, Nirav, Hoang, Bao, Schneider‐Merck, Tanja, Gisbert, Sophie, Carnarius, Heike, Dickson, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596667/
https://www.ncbi.nlm.nih.gov/pubmed/33336508
http://dx.doi.org/10.1111/exd.14253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596667/
https://www.ncbi.nlm.nih.gov/pubmed/33336508
http://dx.doi.org/10.1111/exd.14253

Ejemplares similares